<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Moreau, P.</style></author><author><style face="normal" font="default" size="100%">Palumbo, A.</style></author><author><style face="normal" font="default" size="100%">Chng, W.-J.</style></author><author><style face="normal" font="default" size="100%">Feng, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply</style></title><secondary-title><style face="normal" font="default" size="100%">The Lancet Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84977540032&amp;doi=10.1016%2fS1470-2045%2816%2900145-5&amp;partnerID=40&amp;md5=40c687754e19de4d23dabfa69079747a</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">e126</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">4</style></issue><notes><style face="normal" font="default" size="100%">Export Date: 21 February 2017</style></notes></record></records></xml>